Tadalafil Tablet, Film Coated
Product Images NDC 68071-3929

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3929). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceutical,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3929 3)

Packaging label for Tadalafil 2.5 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets, prescription use only, with storage instructions at controlled temperature 68-77°F. Manufacturer details include Hetero Labs Limited, India. The label displays NDC 68071-3929 and includes barcodes and serial numbers for identification.*

FDA Label Image

Camber1jpj (Camber1jpg)

FDA Label Image

Tadalafilfigure1.jpg (Tadalafilfigure1)

Four graphs showing blood pressure differences over time comparing Tadalafil versus placebo. The graphs include Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, plotted against time in hours. Each graph displays mean differences with error bars at multiple time points up to 96 hours.*

FDA Label Image

Tadalafilfigure2.jpg (Tadalafilfigure2)

This image contains two line graphs comparing the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over a 24-hour post-dose period. The top graph shows standing systolic blood pressure changes, while the bottom graph shows supine systolic blood pressure changes, both measured in mmHg over time in hours.*

FDA Label Image

Tadalafilfigure4.jpg (Tadalafilfigure4)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo in combination with doxazosin. Four groups are compared: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin. The graph tracks blood pressure fluctuations post-dosing.*

FDA Label Image

Tadalafilfigure5.jpg (Tadalafilfigure5)

A pharmacokinetic plot showing plasma tadalafil concentration (µg/L) versus time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph includes error bars and a legend differentiating the regimens.*

FDA Label Image

Tadalfilfigure6.jpg (Tadalafilfigure6)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares two groups: one treated with Tadalafil 5 mg and a placebo group. The Tadalafil group shows a greater decrease in IPSS total score over time compared to placebo. Statistical significance (p<0.01) is noted for differences.*

FDA Label Image

Tadalafilfigure7.jpg (Tadalafilfigure7)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period, comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis represents change from baseline in IPSS total score, with Tadalafil showing a greater decrease compared to placebo.*

FDA Label Image

Tadalafilfigure8 (Tadalafilfigure8)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride. The graph includes data points at weeks 0, 4, 12, and 26, with statistical significance annotations (p < 0.001 and p < 0.05) indicated.*

FDA Label Image

Tadalfilfigure9.jpg (Tadalafilfigure9)

A line graph depicting change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil and placebo groups. The x-axis shows treatment duration in weeks (0, 2, 4, 8, and 12), and the y-axis shows the change in IPSS Total Score. The Tadalafil group shows a more pronounced decrease in score compared to placebo, indicating a treatment effect with statistical significance noted (p<0.01).*

FDA Label Image

Tadalafilstructure.jpg (Tadalafilstructure)

Chemical structure diagram of Tadalafil, depicting its molecular framework including aromatic rings and heterocyclic components, as shown in the product labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.